NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

SUBSEQUENT EVENTS (Details Narrative)

SUBSEQUENT EVENTS (Details Narrative) (USD $)	0 Months Ended		1 Months Ended	3 Months Ended		9 Months Ended		69 Months Ended	1 Months Ended
SUBSEQUENT EVENTS (Details Narrative) (USD $)	Jun. 14, 2013	Mar. 27, 2013	Mar. 31, 2013	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2013	Jul. 24, 2013 Subsequent Event
Exercise of cashless warrants, warrants	1,000	816,000	816,000						50,000
Exercise of cashless warrants, shares	730	554,943							40,458
Restricted shares issued									9,100
Research and development expenses				$ 416,274	$ 353,032	$ 1,428,576	$ 1,040,352	$ 3,854,791	$ 55,667

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References + Details